Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 11 2022
14 11 2022
Historique:
received:
29
04
2022
accepted:
02
11
2022
entrez:
14
11
2022
pubmed:
15
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
SARS-CoV-2 infection, and resulting disease, COVID-19, has a high mortality amongst patients with haematological malignancies. Global vaccine rollouts have reduced hospitalisations and deaths, but vaccine efficacy in patients with haematological malignancies is known to be reduced. The UK-strategy offered a third, mRNA-based, vaccine as an extension to the primary course in these patients. The MARCH database is a retrospective observational study of serological responses in patients with blood disorders. Here we present data on 381 patients with haematological malignancies. By comparison with healthy controls, we report suboptimal responses following two primary vaccines, with significantly enhanced responses following the third primary dose. These responses however are heterogeneous and determined by haematological malignancy sub-type and therapy. We identify a group of patients with continued suboptimal vaccine responses who may benefit from additional doses, prophylactic extended half-life neutralising monoclonal therapies (nMAB) or prompt nMAB treatment in the event of SARS-CoV-2 infection.
Identifiants
pubmed: 36376307
doi: 10.1038/s41467-022-34657-z
pii: 10.1038/s41467-022-34657-z
pmc: PMC9662771
doi:
Substances chimiques
COVID-19 Vaccines
0
Viral Vaccines
0
Antibodies, Viral
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6922Informations de copyright
© 2022. The Author(s).
Références
Lancet. 2022 Feb 12;399(10325):665-676
pubmed: 35151397
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Biomedicines. 2021 Oct 15;9(10):
pubmed: 34680595
Cancer Cell. 2022 Apr 11;40(4):338-339
pubmed: 35216675
BMJ. 2021 Jul 14;374:n1592
pubmed: 34261639
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Lancet. 2022 Mar 5;399(10328):905-907
pubmed: 35090602
Br J Haematol. 2022 Apr;197(1):e1-e4
pubmed: 34923623
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
J Hematol Oncol. 2021 Oct 14;14(1):168
pubmed: 34649563
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480